Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

Abstract Background Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety data from the interim analysis of the real-world NI...

Full description

Saved in:
Bibliographic Details
Main Authors: Ralf Gutzmer, Ulrike Leiter, Peter Mohr, Katharina C. Kähler, Paolo Antonio Ascierto, Massimiliano Scalvenzi, Ketty Peris, Gemma María Pérez-Pastor, Ricardo Fernández-de-Misa, Rafael Botella-Estrada, Robert E. Hunger, Serena Martelli, Nur Güneli, Ramon Arntz, Axel Hauschild
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Cancer
Subjects:
Basal cell carcinoma
Hedgehog pathway inhibitors
Sonidegib
Online Access:https://doi.org/10.1186/s12885-024-13101-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13101-z

Similar Items